EDITORIAL

Zika Virus Infection in Pregnancy

Vorapong Phupong, M.D.*

*Department of Obstetrics and Gynecology, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand

ABSTRACT

Zika virus is a mosquito-borne virus. It is transmitted to humans by infected Aedes spp. mosquitoes. Non-vector-borne transmission routes of Zika virus include blood transfusion-related transmission, sexual transmission, transplacental transmission, and perinatal transmission. Zika virus infection is asymptomatic in most cases. If symptoms occur, symptoms are generally mild and self-limited. Signs and symptoms, diagnosis and treatment of Zika virus infection in pregnant women are similar to non-pregnant women. Zika virus infection in pregnancy is associated with fetal structural brain abnormalities and microcephaly. The treatments are symptomatic and supportive. Prevention from mosquito bites is the best way to prevent Zika virus infection. Treatment of Zika virus infection in pregnant women is similar to non-pregnant women. However, obstetricians should be aware of congenital Zika virus infection when pregnant women infected with Zika virus especially in the first trimester.

Correspondence to: Vorapong Phupong, M.D., Department of Obstetrics and Gynecology, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand. Email: Vorapong.P@chula.ac.th

Zika virus is a mosquito-borne virus. Zika virus is arbovirus (arthropod-borne virus) and is a member of family Flaviviridae, genus Flavivirus. It was discovered in 1947 from a rhesus monkey in the Zika forest in Uganda. Zika virus is transmitted to humans by infected Aedes spp. mosquitoes such as Aedes egypti, Aedes africanus, Aedes albopictus. Zika virus is endemic to Africa and Southeast Asia. Before 2007, few cases of human Zika virus infection had been reported. In 2007, an epidemic of Zika virus infection in humans occurred in Yap, Federated States of Micronesia, in the Pacific region. In 2015, there was a dramatic increase in reports of Zika virus infection especially in pregnant women in Brazil. Zika virus infection was also reported in travelers returning from Africa or Southeast Asia.

Transmission

Zika virus is mainly transmitted by mosquitoes like other flaviviruses. Aedes (Stegomyia) mosquitoes appear to be the most important vector for Zika virus transmission. Non-vector-borne transmission routes of Zika virus have been reported. These include blood transfusion-related transmission, sexual transmission, transplacental transmission, and perinatal transmission.

Signs and symptoms

The incubation period of flaviviruses, such as West Nile virus and dengue virus, is considered to be...
from 3 to 7 days (range = 3–14 days). Zika virus infection is asymptomatic in most cases. If symptoms occur, symptoms are generally mild and self-limited. Symptoms are similar to dengue and chikungunya. It is characterized by mild fever (37.8°C–38.5°C), arthralgia, notably of small joints of hands and feet, myalgia, headache, retroorbital pain, conjunctivitis, and cutaneous maculopapular rash. Rash has been reported 3–5 days after the febrile phase. A non-purulent conjunctivitis is a unique feature of Zika virus infections, and was found in 55% of cases.

Zika virus infection can be misdiagnosed during the acute viremic phase because of nonspecific influenza-like signs and symptoms. Hemorrhagic signs have not been reported in Zika virus infected patients. However neurologic complications, including Guillain-Barré syndrome, have been reported.

**Zika virus infection in pregnancy**

Signs and symptoms, diagnosis and treatment of Zika virus infection in pregnant women are similar to non-pregnant women. Zika virus can cross the placenta and has been detected using RT-PCR analysis of amniotic fluid of pregnancies affected with fetal structural brain abnormalities and microcephaly, and Zika virus has been isolated post-mortem from the brain of a fetus with microcephaly. These findings suggest a strong neurotropism of Zika virus. It is probable that Zika virus infection poses the greatest risk in early pregnancy, although effects throughout pregnancy cannot be excluded.

**Diagnosis**

Diagnostic tests for Zika virus infection include molecular test: reverse transcription PCR (RT-PCR) tests on acute-phase serum samples, which detect viral RNA, and other serologic tests: immunoglobulin M (IgM) ELISA and plaque reduction neutralization test (PRNT) to detect specific antibody against Zika virus in serum. RT-PCR tests can be conducted on samples obtained less than 10 days after illness onset. An ELISA has been developed to detect specific IgM antibody to Zika virus. Cross-reactive antibodies results in sera were demonstrated with other Flavivirus: dengue virus, yellow fever, Japanese encephalitis, Murray Valley encephalitis, and West Nile viruses. This makes the difficult in diagnosis from antibodies result. Thus, it requires confirmation by neutralization assays. IgM was detectable as early as 3 days after onset of illness in some persons. Neutralizing antibody developed as early as 5 days after illness onset. In general, diagnostic testing for flavivirus infections should include an acute-phase serum sample collected as early as possible after onset of illness and a second sample collected 2 to 3 weeks after the first.

Zika virus RNA is detectable in urine by real-time RT-PCR at a higher load and with a longer duration than in serum. Zika virus RNA was detected ≤ 15 days (range 10 days to > 20 days) after onset of symptoms, which was > 7 days after it was not detected in serum samples. Thus, urine might be useful for confirmation of Zika virus infection because virus was detected at higher titers and for a longer period in urine samples than in serum samples.

**Recommended management of pregnant women**

Pregnant women who have a clinical illness consistent with Zika virus disease during or within 2 weeks of travel to areas with ongoing local Zika virus transmission should have Zika virus testing. Pregnant women and their partners should also be aware of the risk for Zika virus infection through unprotected sex with an infected male partner, and carefully follow CDC interim guidelines for preventing sexual transmission of Zika virus infection.

Pregnant women who have a clinical illness consistent with Zika virus disease during or within 2 weeks of travel to areas with ongoing Zika virus transmission should have Zika virus testing. Zika virus testing of maternal serum includes RT-PCR testing for symptomatic patients with onset of symptoms during the previous week; IgM and PRNT testing should be performed on specimens collected ≥4 days after onset of symptoms.

In pregnant women with Zika virus exposure and symptoms, positive Flavivirus serology or proven Zika
virus infection, or in those with exposure and/or symptoms but who have not had positive serology results, referral for detailed ultrasound assessment is appropriate. Measurement of head circumference (HC) to detect microcephaly (HC less than the third percentile for gestational age) and careful assessment of a fetal brain abnormality (such as intracranial calcifications or ventriculomegaly) should be performed\(^{24}\).

**Treatment**

Most cases of Zika virus infections are self-limiting and without significant sequelae\(^{6, 25}\). There is no specific antiviral treatment for Zika virus infection. The treatments are symptomatic and supportive.

**Prevention**

There is no available vaccine to prevent Zika virus infection. When travelling to an affected area of Zika virus, prevention from mosquito bites is the best way to prevent Zika virus infection. Mosquito-bite prevention includes using air conditioning or window and door screens when indoors, wearing long sleeves and pants, using permethrin-treated clothing and gear, and using insect repellents\(^ {26}\).

**References**


